A combination of the ER antagonist and the EGFR tyrosine kinase inhibitor has been shown to decrease cell proliferation and tumor growth more than one individual treatment in both in vitro and in vivo studies [53,97,101,102]. Here, ESR1 is linked to neoplasm.